Literature DB >> 26092203

Evidence against a critical role of CB1 receptors in adaptation of the hypothalamic-pituitary-adrenal axis and other consequences of daily repeated stress.

Cristina Rabasa1, Jordi Pastor-Ciurana1, Raúl Delgado-Morales1, Almudena Gómez-Román1, Javier Carrasco1, Humberto Gagliano1, María S García-Gutiérrez2, Jorge Manzanares2, Antonio Armario3.   

Abstract

There is evidence that endogenous cannabinoids (eCBs) play a role in the control of the hypothalamic-pituitary-adrenal (HPA) axis, although they appear to have dual, stimulatory and inhibitory, effects. Recent data in rats suggest that eCBs, acting through CB1 receptors (CB1R), may be involved in adaptation of the HPA axis to daily repeated stress. In the present study we analyze this issue in male mice and rats. Using a knock-out mice for the CB1 receptor (CB1-/-) we showed that mutant mice presented similar adrenocorticotropic hormone (ACTH) response to the first IMO as wild-type mice. Daily repeated exposure to 1h of immobilization reduced the ACTH response to the stressor, regardless of the genotype, demonstrating that adaptation occurred to the same extent in absence of CB1R. Prototypical changes observed after repeated stress such as enhanced corticotropin releasing factor (CRH) gene expression in the paraventricular nucleus of the hypothalamus, impaired body weight gain and reduced thymus weight were similarly observed in both genotypes. The lack of effect of CB1R in the expression of HPA adaptation to another similar stressor (restraint) was confirmed in wild-type CD1 mice by the lack of effect of the CB1R antagonist AM251 just before the last exposure to stress. Finally, the latter drug did not blunt the HPA, glucose and behavioral adaptation to daily repeated forced swim in rats. Thus, the present results indicate that CB1R is not critical for overall effects of daily repeated stress or proper adaptation of the HPA axis in mice and rats.
Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  AM251; Cannabinoids; Chronic stress; Habituation

Mesh:

Substances:

Year:  2015        PMID: 26092203     DOI: 10.1016/j.euroneuro.2015.04.026

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  5 in total

Review 1.  2-Arachidonoylglycerol Modulation of Anxiety and Stress Adaptation: From Grass Roots to Novel Therapeutics.

Authors:  Gaurav Bedse; Mathew N Hill; Sachin Patel
Journal:  Biol Psychiatry       Date:  2020-03-17       Impact factor: 13.382

2.  Extremely low frequency electromagnetic field exposure and restraint stress induce changes on the brain lipid profile of Wistar rats.

Authors:  Jesús Martínez-Sámano; Alan Flores-Poblano; Leticia Verdugo-Díaz; Marco Antonio Juárez-Oropeza; Patricia V Torres-Durán
Journal:  BMC Neurosci       Date:  2018-05-21       Impact factor: 3.288

Review 3.  Endocannabinoids in Body Weight Control.

Authors:  Henrike Horn; Beatrice Böhme; Laura Dietrich; Marco Koch
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-30

4.  Peptidergic neurons of the Edinger-Westphal nucleus express TRPA1 ion channel that is downregulated both upon chronic variable mild stress in male mice and in humans who died by suicide.

Authors:  Viktória Kormos; Angéla Kecskés; József Farkas; Tamás Gaszner; Valér Csernus; Ammar Alomari; Dániel Hegedüs; Éva Renner; Miklós Palkovits; Dóra Zelena; Zsuzsanna Helyes; Erika Pintér; Balázs Gaszner
Journal:  J Psychiatry Neurosci       Date:  2022-05-04       Impact factor: 5.699

5.  Fluoxetine treatment supports predictive validity of the three hit model of depression in male PACAP heterozygous mice and underpins the impact of early life adversity on therapeutic efficacy.

Authors:  Tamás Gaszner; József Farkas; Dániel Kun; Balázs Ujvári; Gergely Berta; Valér Csernus; Nóra Füredi; László Ákos Kovács; Hitoshi Hashimoto; Dóra Reglődi; Viktória Kormos; Balázs Gaszner
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-23       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.